Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY1 | P47900 | 7/20 | 0.69 |
| ▸ | P2RY2 | P41231 | 3/20 | 0.69 |
| ▸ | SRC | P12931 | 2/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.69 |
| ▸ | P2RX1 | P51575 | 2/20 | 0.69 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.69 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.69 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.69 |
| ▸ | ADH1A | P07327 | 1/20 | 0.66 |
| ▸ | TRPM2 | O94759 | 2/20 | 0.66 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.66 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.66 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.66 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.66 |
| ▸ | LDHA | P00338 | 1/20 | 0.66 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.66 |
| ▸ | FBP1 | P09467 | 1/20 | 0.66 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.66 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL811714 | 0.91 | P2RY1 (0.63) | P2RY1P2RY2SRCSMN1; SMN2P2RX1 | |
| Adenosine Diphosphate SCHEMBL570243 | 0.89 | ADH1A (0.74) | P2RY1P2RY2SRCSMN1; SMN2P2RX1 | |
| Adenosine Phosphate SCHEMBL810818 | 0.88 | DNPH1 (0.75) | P2RY1P2RY2SRCSMN1; SMN2P2RX1 | |
| Adenosine Phosphate SCHEMBL160972 | 0.88 | P2RY1 (0.75) | P2RY1P2RY2SRCSMN1; SMN2P2RX1 | |
| Adenosine Phosphate SCHEMBL27419541 | 0.88 | P2RY1 (0.75) | P2RY1P2RY2SRCSMN1; SMN2P2RX1 | |
| Adenosine Triphosphate SCHEMBL811713 | 0.88 | P2RY1 (0.72) | P2RY1P2RY2SRCSMN1; SMN2P2RX1 | |
| Adenosine Triphosphate SCHEMBL811698 | 0.88 | ADH1A (0.75) | P2RY1P2RY2SRCSMN1; SMN2P2RX1 | |
| SCHEMBL29169618 | 0.88 | GSK3A (0.71) | P2RY1P2RY2SRCSMN1; SMN2P2RX1 | |
| Niacinamide SCHEMBL28249016 | 0.85 | ADH1A (0.66) | P2RY1P2RY2SRCSMN1; SMN2P2RX1 | |
| SCHEMBL8859838 | 0.85 | P2RY1 (0.61) | P2RY1P2RY2SRCSMN1; SMN2P2RX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040081672-A1 | Niacinamide, niacin, and niacin esters based delivery systems for treating topical disorders of skin and skin aging | GUPTA SHYAM K (US) | 2004-04-29 | — | — | US | claimed |
| US-20160220536-A1 | USE OF PHENYLMETHIMAZOLES, METHIMAZOLE DERIVATIVES, AND TAUTOMERIC CYCLIC THIONES FOR THE TREATMENT OF AUTOIMMUNE/INFLAMMATORY DISEASES ASSOCIATED WITH TOLL-LIKE RECEPTOR OVEREXPRESSION | UNIV OHIO (US) | 2016-08-04 | — | — | US | disclosed |
| US-9326972-B2 | Use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune/inflammatory diseases associated with toll-like receptor overexpression | OHIO UNIVERSITY (US) | 2016-05-03 | — | — | US | disclosed |
| US-20120238610-A1 | Use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune/inflammatory diseases associated with toll-like receptor overexpression | OHIO UNIVERSITY | 2012-09-20 | — | — | US | disclosed |
| EP-2399578-A1 | Methods and compositions for the treatment of autoimmune and inflammatory diseases associated with toll-like receptors | The Interthyr Corporation (US) | 2011-12-28 | — | — | EP | disclosed |
| US-20100004304-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF MALIGNANT MELANOMA, BREAST, PROSTATE, COLON, PAPILLARY THYROID AND PANCREATIC CANCER | OHIO UNIVERSITY | 2010-01-07 | — | — | US | disclosed |
| EP-1896015-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISEASES ASSOCIATED WITH TOLL-LIKE RECEPTORS | The Interthyr Corporation (US) | 2008-03-12 | — | — | EP | disclosed |
| WO-2006124676-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISEASES ASSOCIATED WITH TOLL-LIKE RECEPTORS | THE INTERTHYR CORPORATION (US) | 2006-11-23 | — | — | WO | disclosed |
| US-20060211752-A1 | Use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune/inflammatory diseases associated with toll-like receptor overexpression | BENAVIDES-PERALTA, URUGUAYSITO LORELEY (UY) | 2006-09-21 | — | — | US | disclosed |
| US-20060147508-A1 | Concurrent Enhancement of Skin Penetration of Organic Base Active Agents and Organic Hydroxy Acid Active Agents as Their Ion-Pair Complexes | BIODERM RESEARCH (US) | 2006-07-06 | — | — | US | disclosed |
| US-20040081672-A1 | Niacinamide, niacin, and niacin esters based delivery systems for treating topical disorders of skin and skin aging | GUPTA SHYAM K (US) | 2004-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060211752-A1 | Use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune/inflammatory diseases associated with toll-like receptor overexpression | TLR3, IRF3, TLR4 | P2RY1 397/4885P2RY2 711/4885SRC 575/4885 |
| US-20120238610-A1 | Use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune/inflammatory diseases associated with toll-like receptor overexpression | IRF3, TLR3, TLR4 | P2RY1 590/4885P2RY2 867/4885SRC 463/4885 |
| US-20160220536-A1 | USE OF PHENYLMETHIMAZOLES, METHIMAZOLE DERIVATIVES, AND TAUTOMERIC CYCLIC THIONES FOR THE TREATMENT OF AUTOIMMUNE/INFLAMMATORY DISEASES ASSOCIATED WITH TOLL-LIKE RECEPTOR OVEREXPRESSION | IRF3, TLR3, TLR4 | P2RY1 590/4885P2RY2 867/4885SRC 463/4885 |
| US-20100004304-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF MALIGNANT MELANOMA, BREAST, PROSTATE, COLON, PAPILLARY THYROID AND PANCREATIC CANCER | STAT3, STAT6, TLR3 | P2RY1 2570/4885P2RY2 2747/4885SRC 177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.